Icaritin with TACE, immunotherapy, and targeted therapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an oral herbal medicine (Icaritin) to standard combination therapy (TACE, immunotherapy, and targeted therapy) works better than the standard combination alone for advanced liver cancer that cannot be removed with surgery. It may be a good option if you haven't had whole-body cancer treatment before and your liver is still working well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and have advanced liver cancer (HCC) that cannot be removed by surgery.
- You have not had any whole-body cancer treatment before, or your cancer came back after surgery and you haven't had whole-body treatment.
- You are able to have a procedure called TACE (chemo directly into your liver artery), and your tumors are not too large or too many (up to 10, largest less than 10 cm, less than half of your liver affected).
- You are in good general health (ECOG 0 or 1) and your liver is working well (Child-Pugh A).
- Your blood counts, kidney, and liver lab tests are within certain safe limits, and your blood pressure is controlled with up to 3 medications.
- You are not pregnant, can take oral pills, and have no history of recent severe bleeding, blood clots, or autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy (HAIC) with the immunotherapy drugs atezolizumab and bevacizumab for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
This trial tests combining a natural compound (Icaritin) with standard chemotherapy (mFOLFOX) after liver cancer surgery to lower the chance of the cancer coming back. It is for patients whose cancer had certain high-risk features, like a large tumor or cancer in blood vessels.
This trial tests combining a targeted medicine (Icaritin) with a procedure that delivers chemotherapy directly to the liver (TACE) after surgery. It is for people with liver cancer who have a high chance of the cancer coming back, to see if this treatment helps prevent recurrence.
This trial tests whether taking icariin soft capsules along with a liver-directed treatment called TACE can help prevent liver cancer from coming back after surgery or ablation. It is for people who have had their tumor removed but still have risk factors that make recurrence more likely.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.